rs374349989
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1_ModeratePM2PP5_Very_Strong
The NM_024809.5(TCTN2):c.1506-2A>G variant causes a splice acceptor, intron change. The variant allele was found at a frequency of 0.0000205 in 1,608,974 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: 𝑓 0.000013 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000021 ( 0 hom. )
Consequence
TCTN2
NM_024809.5 splice_acceptor, intron
NM_024809.5 splice_acceptor, intron
Scores
3
3
1
Splicing: ADA: 1.000
2
Clinical Significance
Conservation
PhyloP100: 5.98
Genes affected
TCTN2 (HGNC:25774): (tectonic family member 2) This gene encodes a type I membrane protein that belongs to the tectonic family. Studies in mice suggest that this protein may be involved in hedgehog signaling, and essential for ciliogenesis. Mutations in this gene are associated with Meckel syndrome type 8. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2011]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PVS1
Splicing +-2 bp (donor or acceptor) variant, product NOT destroyed by NMD, known LOF gene, truncates exone, which is 0.05062082 fraction of the gene. Cryptic splice site detected, with MaxEntScore 4, offset of -48, new splice context is: ttcactggaaatgactttAGgac. Cryptic site results in inframe change. If cryptic site found is not functional and variant results in exon loss, it results in frameshift change.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 12-123699702-A-G is Pathogenic according to our data. Variant chr12-123699702-A-G is described in ClinVar as [Likely_pathogenic]. Clinvar id is 31076.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr12-123699702-A-G is described in Lovd as [Pathogenic]. Variant chr12-123699702-A-G is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TCTN2 | NM_024809.5 | c.1506-2A>G | splice_acceptor_variant, intron_variant | ENST00000303372.7 | NP_079085.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TCTN2 | ENST00000303372.7 | c.1506-2A>G | splice_acceptor_variant, intron_variant | 1 | NM_024809.5 | ENSP00000304941.5 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152110Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
2
AN:
152110
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000159 AC: 4AN: 251140Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135806
GnomAD3 exomes
AF:
AC:
4
AN:
251140
Hom.:
AF XY:
AC XY:
3
AN XY:
135806
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000213 AC: 31AN: 1456864Hom.: 0 Cov.: 31 AF XY: 0.0000221 AC XY: 16AN XY: 725018
GnomAD4 exome
AF:
AC:
31
AN:
1456864
Hom.:
Cov.:
31
AF XY:
AC XY:
16
AN XY:
725018
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152110Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74338
GnomAD4 genome
AF:
AC:
2
AN:
152110
Hom.:
Cov.:
32
AF XY:
AC XY:
0
AN XY:
74338
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
1
ExAC
AF:
AC:
2
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:11
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Feb 25, 2022 | Canonical splice site variant in a gene for which loss-of-function is a known mechanism of disease; Published functional studies demonstrate that normal splicing is abolished and two abberant transcripts are created (Shaheen et al., 2011); Not observed at a significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 21462283, 26729329, 23169490, 31428121, 32055034, 31589614, 32552793) - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jul 14, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Sep 01, 2023 | TCTN2: PVS1, PM2 - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jan 19, 2023 | - - |
Meckel-Gruber syndrome;C0431399:Familial aplasia of the vermis Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 25, 2023 | This sequence change affects an acceptor splice site in intron 13 of the TCTN2 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in TCTN2 are known to be pathogenic (PMID: 21565611). This variant is present in population databases (rs374349989, gnomAD 0.008%). Disruption of this splice site has been observed in individual(s) with clinical features of TCTN2-related conditions (PMID: 21462283, 31428121). ClinVar contains an entry for this variant (Variation ID: 31076). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
Joubert syndrome 24 Pathogenic:1
Pathogenic, criteria provided, single submitter | research | Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center | Mar 17, 2024 | - - |
Meckel syndrome, type 8 Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Jun 01, 2011 | - - |
TCTN2-related disorder Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | The TCTN2 c.1506-2A>G variant occurs in a canonical splice site (acceptor) and is therefore predicted to disrupt or distort the normal gene product. The c.1506-2A>G variant has been reported in three studies in which it is found in a homozygous state in at least six patients and in a heterozygous state in one patient in whom a second variant was not identified (Shaheen et al. 2011; Shaheen et al. 2013; Watson et al. 2016). Three of the homozygotes were diagnosed with Meckel syndrome and three patients were noted to be on the Joubert-Meckel syndrome spectrum but the individual clinical phenotypes were not provided (Watson et al. 2016). The c.1506-2A>G variant was absent from at least 192 controls and is reported at a frequency of 0.00012 in the European-American population of the Exome Sequencing Project but this is based on one allele only. RT-PCR experiments showed the variant completely abolished normal splicing and created two aberrant transcripts (Shaheen et al. 2011). Based on the evidence, the c.1506-2A>G variant is classified as pathogenic for TCTN2-related disorders. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Joubert syndrome and related disorders Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 12, 2024 | Variant summary: TCTN2 c.1506-2A>G is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Four predict the variant abolishes a 3' acceptor site. At least one publication reports experimental evidence confirming that this variant affects mRNA splicing (Maddirevula_2020). The variant allele was found at a frequency of 1.6e-05 in 251140 control chromosomes (gnomAD). c.1506-2A>G has been reported in the literature in multiple individuals affected with Joubert Syndrome And Related Disorders (e.g. Shaheen_2016, Maddirevula_2020, Watson_2016). These data indicate that the variant is very likely to be associated with disease. ClinVar contains an entry for this variant (Variation ID: 31076). Based on the evidence outlined above, the variant was classified as pathogenic. - |
Meckel syndrome, type 8;C4084841:Joubert syndrome 24 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Jan 25, 2024 | - - |
Meckel syndrome, type 6 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Pathology and Clinical Laboratory Medicine, King Fahad Medical City | - | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Uncertain
CADD
Uncertain
DANN
Uncertain
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Uncertain
D
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Pathogenic
dbscSNV1_RF
Pathogenic
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_AL_spliceai
Position offset: 2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at